Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 493

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase

Greig, Nigel H., Utsuki, Tada, Yu, Qian-Sheng, Zhu, Xiaoxiang, Holloway, Harold W., Perry, Tracyann, Lee, Bong, Ingram, Donald K., Lahiri, Debomoy K.·2001·Current Medical Research and Opinion

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the elderly, characterised by widespread loss of central cholinergic function. The only symptomatic treatment proven effective to date is the use of cholinesterase (ChE) inhibitors to augment surviving cholinergic activity. ChE inhibitors act on the enzymes that hydrolyse acetylcholine (ACh) following synaptic release. In the healthy brain, acetylcholinesterase (AChE) predominates (80%) and butyrylcholinesterase (BuChE) is considered to play a minor role in regulating brain ACh levels. In the AD brain, BuChE activity rises while AChE activity remains unchanged or declines. Therefore both enzymes are likely to have involvement in regulating ACh levels and represent legitimate therapeutic targets to ameliorate the cholinergic deficit. The two enzymes differ in location, substrate specificity and kinetics. Recent evidence suggests that BuChE may also have a role in the aetiology and progression of AD beyond regulation of synaptic ACh levels. Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine, MF-8622) and ChE inhibitors such as rivastigmine, which have a dual inhibitory action on both AChE and BuChE, indicate potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias. The development of specific BuChE inhibitors and the continued use of ChE inhibitors with the ability to inhibit BuChE in addition to AChE should lead to improved clinical outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1185/03007990152673800

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 493

Metadata

Authors
Greig, N. H., Utsuki, T., Yu, Q.-S., Zhu, X., Holloway, H. W., Perry, T., Lee, B., Ingram, D. K., & Lahiri, D. K.
Venue
Current Medical Research and Opinion
Published
2001-11-23
Volume
17
Issue
3
Pages
159-165
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W4248650858
Cited by
493
References
2
FWCI
5.99
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase. https://app.cochat.ai/papers/10.1185/03007990152673800
The paper
Greig, N. H., Utsuki, T., Yu, Q.-S., Zhu, X., Holloway, H. W., Perry, T., Lee, B., Ingram, D. K., & Lahiri, D. K. (2001). A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase. Current Medical Research and Opinion. https://doi.org/10.1185/03007990152673800

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.